Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus

The hepatitis C virus protease inhibitor telaprevir is an inhibitor of the enzyme cytochrome P450 3A, responsible for the metabolism of both cyclosporine and tacrolimus. This Phase I, open‐label, nonrandomized, single‐sequence study assessed the effect of telaprevir coadministration on the pharmacokinetics of a single dose of either cyclosporine or tacrolimus in two separate panels of 10 healthy volunteers each. In Part A, cyclosporine was administered alone as a single 100‐mg oral dose, followed by a minimum 8‐day washout period, and subsequent coadministration of a single 10‐mg oral dose of cyclosporine with either a single dose of telaprevir (750 mg) or with steady‐state telaprevir (750 mg every 8 hours [q8h]). In Part B, tacrolimus was administered alone as a single 2‐mg oral dose, followed by a minimum 14‐day washout period, and subsequent coadministration of a single 0.5‐mg dose of tacrolimus with steady‐state telaprevir (750 mg q8h). Coadministration with steady‐state telaprevir increased cyclosporine dose‐normalized (DN) exposure (DN_AUC0‐∞) by approximately 4.6‐fold and increased tacrolimus DN_AUC0‐∞ by approximately 70‐fold. Coadministration with telaprevir increased the terminal elimination half‐life (t½) of cyclosporine from a mean (standard deviation [SD]) of 12 (1.67) hours to 42.1 (11.3) hours and t½ of tacrolimus from a mean (SD) of 40.7 (5.85) hours to 196 (159) hours. Conclusion: In this study, telaprevir increased the blood concentrations of both cyclosporine and tacrolimus significantly, which could lead to serious or life‐threatening adverse events. Telaprevir has not been studied in organ transplant patients; its use in these patients is not recommended because the required studies have not been completed to understand appropriate dose adjustments needed for safe coadministration of telaprevir with cyclosporine or tacrolimus, and regulatory approval has not been obtained. (HEPATOLOGY 2011;)